NDA 215344 · Azurity
Suflave
Magnesium Sulfate, Polyethylene Glycol 3350, Potassium Chloride, Sodium Chloride, Sodium Sulfate · Oral
Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jun 15, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 1 recruiting
FAERS reports
108
15 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
SUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUFLAVE is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 15, 2023 Original approval · Type 4 - New Combination LabelMedication GuideLetter
1 products under this application
- SUFLAVE · MAGNESIUM SULFATE 0.9GM/BOT; POLYETHYLENE GLYCOL 3350 178.7GM/BOT; POTASSIUM CHLORIDE 1.12GM/BOT; SODIUM CHLORIDE 0.5GM/BOT; SODIUM SULFATE 7.3GM/BOT · FOR SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Suflave" as an intervention, any sponsor and status, largest first.
- Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) TrialPivotal-lookingRecruiting
Morehouse School of MedicineAcademic, hospital or other
NCT07215000 · 300 participants (planned) · Start Oct 1, 2025 · Primary completion Jan 2027
Drug: Golytely; Sulfave and 1 more · For: Colorectal Cancer Screening; Bowel Cleansing for Colonoscopy
Sites: Atlanta, Georgia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea29
- vomiting23
- abdominal distension12
- headache10
- dehydration8
- drug ineffective8
- pruritus8
- abdominal pain7
- dizziness7
- urticaria7
- abdominal pain upper5
- asthenia5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2024 | 39 |
| 2025 | 47 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Suflave (PEG 3350/Sod Sulf,Chlr/Pot/Mag)
2024 spending
$3.7M
Beneficiaries
29,704
30,370 claims
Per beneficiary
$125
$61.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $461,517 |
| 2024 | $3,717,028 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.